Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12128109 Muscle targeting complexes and formulations for treating dystrophinopathies

Patent 12128109 was granted and assigned to Dyne Therapeutics on October, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Dyne Therapeutics

0

Current Assignee

Dyne Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Scott Hilderbrand0

Sean Spring0

Cody A. Desjardins0

Romesh R. Subramanian0

Mohammed T. Qatanani0

Brendan Quinn0

Peiyi Shen0

Timothy Weeden0

...

Date of Patent

October 29, 2024

0

Patent Application Number

184553510

Date Filed

August 24, 2023

0

Patent Citations

US Patent 7960541 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

0

US Patent 7973015 Induction of exon skipping in eukaryotic cells

0

US Patent 8084601 Oligomers

0

US Patent 8232384 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

0

US Patent 8324371 Oligomers

0

US Patent 8361979 Means and method for inducing exon-skipping

0

US Patent 8455636 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

0

US Patent 8486907 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12128109 Muscle targeting complexes and formulations for treating dystrophinopathies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool